Juan Luis Callejas‐Valera

Author

National Institute of Dental and Craniofacial Research ORCID

Also Known As

J L Callejas-Valera, J. Callejas-Valera, J. L. Callejas-Valera, Juan L. Callejas-Valera, Juan L. Callejas‐Valera, Juan Luis Callejas-Valera, Juan Luis Callejas‐Valera

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

National Institute of Dental and Craniofacial Research University of California San Diego Sanford Research University of Castilla-La Mancha National Institutes of Health

About

Juan Luis Callejas‐Valera is an author at National Institute of Dental and Craniofacial Research specializing in cell biology, medicine, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	296
2	Cell Biology	6	6	296
3	Immunology	3	3	123
4	Molecular Biology	1	1	40
5	Pathology	1	1	39

Juan Luis Callejas‐Valera

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Transcriptional signature primes human oral mucosa for rapid wound healing Ramiro Iglesias‐Bartolomé, Akihiko Uchiyama, Alfredo Molinolo, Science Translational Medicine	2018	270
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4 Zhiyong Wang, Victoria H. Wu, Michael M. Allevato, Nature Communications	2019	166
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study Steven Powell, Kathryn A. Gold, Mark M. Gitau, Journal of Clinical Oncology	2020	117
RETRACTED ARTICLE: P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance Miguel Ángel de la Cruz-Morcillo, María Llanos Valero, Juan Luis Callejas‐Valera, Oncogene Tumor BiologyMitophagyCell AutophagyMedicineReceptor Tyrosine Kinase	2011	115
HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers Shuling Ren, Daria A. Gaykalova, Theresa Guo, Oncogene	2020	94
ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy Clara Aceves-Luquero, Anupriya Agarwal, Juan Luis Callejas‐Valera, PLoS ONE Hematological MalignancySystems BiologySignal TransductionCell RegulationMedicine	2009	47
ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma Laura Arias‐González, Inmaculada Moreno, Antonio Rubio‐del‐Campo, Neoplasia	2013	40
Balance between MKK6 and MKK3 Mediates p38 MAPK Associated Resistance to Cisplatin in NSCLC Eva María Galán‐Moya, Miguel Ángel de la Cruz-Morcillo, María Llanos Valero, PLoS ONE Chemoprevention StrategyMolecular BiologyP38 MapkCell CycleTumor Biology	2011	40
mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model Juan Luis Callejas‐Valera, Ramiro Iglesias‐Bartolomé, Panomwat Amornphimoltham, Carcinogenesis Mtor ActivationOncogenic AgentMtor InhibitionImmunologyPathology	2016	39
c‐Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin‐based therapy Eva María Galán‐Moya, Javier Hernández‐Losa, Clara Isabel Aceves Luquero, International Journal of Cancer Cancer ResearchSignaling PathwayCell RegulationMedicineReceptor Tyrosine Kinase	2007	37

Page 1